Entertainment
Education
Health
Dr Batra’s® Introduces HairGain — India’s First Advanced Hair Regrowth Treatment Powered by 50 Billion Exosomes
Novel exosome-powered therapy marks a new milestone in regenerative hair restoration, offering a non-surgical solution built on Dr Batra’s® proprietary TriXo Complex
Mumbai (Maharashtra) [India], August 3: Marking a new milestone in regenerative medicine, Dr Batra’s® Healthcare today announced the launch of HairGain, India’s first advanced hair regrowth treatment powered by 50 Billion Exosomes, bringing one of the world’s most promising regenerative technologies to patients seeking a non-surgical solution for hair restoration.
Hair loss is no longer just a cosmetic concern — it has become an emotional and confidence-impacting issue for 150 million people across India, spanning age groups. From hereditary hair loss and post-pregnancy hair fall to menopause-related thinning and stress-induced hair loss, people are increasingly seeking effective solutions that go beyond managing hair fall to actually promoting natural hair regrowth.
HairGain has been developed for men and women experiencing different stages and causes of hair loss, including hereditary hair loss (male and female pattern baldness), post-pregnancy hair fall, post-menopausal hair thinning, stress-induced hair loss and early-stage hair thinning. By delivering powerful regenerative signals directly to the scalp, HairGain works to stimulate dormant hair follicles, improve scalp health and encourage the body’s natural hair growth process — helping restore thicker, denser and healthier-looking hair over time.
At the heart of HairGain is an advanced formulation powered by 50 Billion Exosomes — tiny biological messengers that play a critical role in cell-to-cell communication and tissue regeneration. These exosomes help activate dormant follicles, promote cellular repair and create an optimal environment for new hair growth.
The treatment is built around Dr Batra’s® proprietary TriXo Complex, a multi-layered regenerative approach that combines the power of exosomes with scientifically selected ingredients including PDRN (Polydeoxyribonucleotide), collagen, caffeine, growth factors, polypeptides and copper tripeptides. Together, these ingredients work synergistically to regenerate damaged follicles, improve scalp microcirculation, strengthen the scalp barrier, extend the active growth phase of hair and enhance hair density and quality — supporting healthier hair growth from the root while improving the strength and resilience of existing hair.
HairGain is expected to deliver visible improvements in approximately 75 days, depending on an individual’s condition and treatment protocol. Patients can expect healthier scalp conditions, reduced hair fall, stronger hair roots, improved hair thickness and density, and noticeable hair regrowth under expert clinical guidance — making it one of the fastest non-surgical regenerative hair restoration solutions offered by Dr Batra’s®.
Commenting on the launch, Dr. Akshay Batra, Vice-Chairman and Managing Director, Dr Batra’s® Healthcare, and the first Indian President of the Trichological Society of London (UK), said:

“Hair restoration is entering a completely new era. Today’s consumers are looking for solutions that are backed by science, are minimally invasive and capable of delivering meaningful hair regrowth by working with the body’s own regenerative mechanisms. Exosome therapy represents one of the most exciting advances in regenerative medicine because it delivers powerful biological signals that help awaken dormant hair follicles and support natural hair growth.”
“Unlike PRP, where results can vary depending on the quality and concentration of an individual’s own platelets, HairGain delivers a standardized dose of 50 Billion Exosomes, ensuring a far more consistent regenerative stimulus for the scalp. For many individuals experiencing early to moderate stages of hair loss, this offers a compelling non-surgical option that may help restore hair naturally before considering more invasive procedures such as hair transplantation.”
With over four decades of expertise in hair and scalp care, Dr Batra’s® Healthcare continues to invest in next-generation regenerative therapies that combine medical science, clinical research and innovation. The launch of HairGain marks another significant milestone in the company’s mission to make advanced global technologies accessible to Indian consumers and redefine the future of hair restoration with safe, science-backed and personalized treatment solutions.
About Dr Batra’s® Healthcare
With over 200+ clinics in around 130 cities across 10 countries including India, Bangladesh, UK, UAE, Thailand, Malaysia and Bahrain Dr Batra’s® Homeopathy Clinics has over 350 doctors including skin specialists, hair specialists, and experienced homeopathic doctors. Dr Batra’s® specializes in Hair, Skin, Allergies, Child and Women’s Health, Mental Health, Sexual Health, and Weight Management ailments including Hair loss, Vitiligo, Psoriasis, Acne, Low immunity, Tonsillitis, Stress Management, Migraine, Thyroid, PCOS, Menopause, Allergies, Sexual Health, Weight Management and Infertility.
For more information, visit www.drbatras.com.
If you object to the content of this press release, please notify us at [email protected]. We will respond and rectify the situation within 24 hours.
Business
Master Trust Reports Q1 FY27 Performance with 13.8% Growth in Total Income & 27.8% Surge in PAT
Ludhiana (Punjab) [India], August 5: Master Trust Limited (MASTERTR, BSE: 511768), a diversified financial services company offering broking, lending, wealth management, portfolio management, and investment solutions through a strong digital platform, has reported its Unaudited Financial Results for Q1 FY27.
Key Financial Highlights
Key Financial Highlights Q1 FY27:
- Total Income of ₹1,497.9 Mn, YoY growth of 13.8%
- EBITDA of ₹618.3 Mn, YoY growth of 19.3%
- EBITDA Margin of 41.3%, YoY expansion of 190 bps
- PAT of ₹346.5 Mn, YoY growth of 27.8%
- PAT Margin of 23.1%, YoY expansion of 250 bps
- EPS of ₹2.8, YoY growth of 16.7%
Consolidated Revenue Mix by Business Segment
- Broking & Allied remained the largest revenue contributor, accounting for ~94.5% of total revenue in Q1 FY27, supported by healthy growth in core broking operations.
- Investment / Trading in Securities & Others recorded strong growth of 184.8% YoY, reflecting higher treasury and investment-related income.
- The Portfolio Management Services contributed ₹27.9 Mn during the quarter and Insurance Broking contributed ₹9.4 Mn, complementing the Company’s diversified financial services platform.
- The Company’s diversified presence across broking, investment services, portfolio management, insurance broking, and treasury operations continues to strengthen its business model and support long-term growth.
Commenting on the performance, Mr. Harjeet Singh Arora, Managing Director of Master Trust Limited and Master Capital Services Limited, said, “During the quarter, we delivered healthy financial performance, with Total Income growing by 13.8% YoY to ₹1,497.9 Mn, EBITDA increasing by 19.3% YoY to ₹618.3 Mn, and PAT rising by 27.8% YoY to ₹346.5 Mn. Profitability also improved, with EBITDA Margin expanding by 190 bps to 41.3% and PAT Margin increasing by 250 bps to 23.1%, reflecting disciplined execution, operational efficiency, and the strength of our diversified financial services platform.
Operationally, the quarter marked another important milestone with the successful listing of our NCDs on the NSE Debt Segment. This listing strengthens our capital structure, enhances financial flexibility, and further diversifies our funding sources, supporting the Company’s long-term growth strategy.
Going forward, we remain focused on strengthening our core businesses, maintaining prudent capital allocation, and leveraging our robust financial position to drive sustainable growth. We remain confident in our ability to create long-term value for our stakeholders through disciplined execution, innovation, and a customer-centric approach.
About Master Trust Limited
Master Trust Limited is a diversified financial services company with over 41 years of experience, offering a comprehensive suite of trading, investment, wealth management, and financial solutions. Established in 1985, the Company has evolved into a trusted financial services platform with a strong presence across capital markets, serving retail, HNI, corporate, and institutional clients through technology-driven and research-backed offerings.
The Company has built a pan-India network spanning 22 states, with 63 branches, 1,460+ business partners, over 4.36 lakh registered customers, and a workforce of 1,290+ employees, reflecting its strong distribution capabilities and customer reach.
Master Trust provides a one-stop financial services platform, offering equity and commodity trading, derivatives, portfolio management, wealth management, depository services, merchant banking, insurance, research, algorithmic trading, and NBFC services. This diversified product portfolio enables the Company to cater to the evolving financial needs of investors under a single integrated ecosystem.
Over the years, the Company has strengthened its market position through continuous technology adoption, digital innovation, and strategic expansion. It has received several industry recognitions, including being named the Best BFSI Brand by The Economic Times for four consecutive years (2023–2026) and the Best Organisation to Work by ET Now in 2025, underscoring its commitment to operational excellence and customer-centricity.
Looking ahead, Master Trust aims to deepen its digital capabilities, expand its customer base and product offerings, and strengthen its integrated financial services ecosystem. With a focus on technology, innovation, research-driven advisory, and nationwide expansion, the Company is well-positioned to capitalize on the growing demand for comprehensive financial solutions while creating long-term value for its stakeholders.
In FY26 (Consolidated), Master Trust Limited reported Total Income of ₹5,758.5 Mn, EBITDA of ₹ 2361.7 Mn, and Net Profit of ₹1,260.9 Mn.
If you object to the content of this press release, please notify us at [email protected]. We will respond and rectify the situation within 24 hours.
